Get the Stockscreener App
29.73
2.41%
0.70
After Hours:
29.43
-0.30
-1.01%
Apellis Pharmaceuticals Inc stock is traded at $29.73, with a volume of 1.31M.
It is up +2.41% in the last 24 hours and down -11.68% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$29.03
Open:
$29.15
24h Volume:
1.31M
Relative Volume:
0.46
Market Cap:
$3.70B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-14.65
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-9.91%
1M Performance:
-11.68%
6M Performance:
-27.75%
1Y Performance:
-55.16%
1-Day Range:
$29.15
$30.12
1-Week Range:
$27.35
$30.38
52-Week Range:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
29.73 | 3.70B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.38B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.18B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.81 | 39.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.03B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
IC-MPGN Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Novartis, Apellis Pharmaceuticals - The Globe and Mail
IC-MPGN Market Revenue to Expand Significantly by 2034, States - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect - AccessWire
Layoff Tracker: Apellis, Barinthus, Repare Among Latest to Trim Workforces - BioSpace
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals chief people officer sells $45,894 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals VP sells shares worth $22,473 By Investing.com - Investing.com Canada
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock - Investing.com India
Apellis Pharmaceuticals CFO sells shares worth $62,283 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals chief development officer sells shares worth $7,577 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $62,279.00 in Stock - MarketBeat
David O. Watson Sells 4,965 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals chief scientific officer sells $65,670 in stock By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals officer sells shares worth $77,065 By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals CTO Nicholson Nur sells shares worth $75,543 - Investing.com India
Apellis Pharmaceuticals officer sells shares worth $77,065 - Investing.com India
Apellis Pharmaceuticals CFO sells shares worth $62,283 - Investing.com
Apellis Pharmaceuticals chief people officer sells $45,894 in stock - Investing.com
James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $179,288.90 in Stock - MarketBeat
Apellis Pharmaceuticals general counsel sells shares worth $142,505 By Investing.com - Investing.com UK
Apellis Pharmaceuticals CEO Cedric Francois sells shares worth $179,302 - Investing.com
Apellis Pharmaceuticals chief business officer sells shares totaling $45,894 - Investing.com
Apellis Pharmaceuticals VP sells shares worth $22,473 - Investing.com
HC Wainwright Reaffirms "Buy" Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation - AccessWire
Apellis stock jumps 8% on preliminary Q4 results, updates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpHere's What Happened - MarketBeat
Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes - TipRanks
Apellis reports $709 million in 2024 revenue, plans for growth - Investing.com
Apellis reports $709 million in 2024 revenue, plans for growth By Investing.com - Investing.com UK
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Apellis Reports Strong $709M Revenue as SYFOVRE Sales Surge 120%, Announces Leadership Changes - StockTitan
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm - AccessWire
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's Why - MarketBeat
Apellis Announces Keli Walbert to Join the Board of Directors - The Manila Times
What’s Driving Apellis Pharmaceuticals Stock Down? - TipRanks
Apellis Pharmaceuticals Strengthens Board with TEPEZZA Launch Veteran Keli Walbert - StockTitan
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 2,816 Shares of Stock - MarketBeat
Apellis Pharmaceuticals chief medical officer sells $95,214 in stock - Investing.com
Apellis Pharmaceuticals chief medical officer sells $95,214 in stock By Investing.com - Investing.com UK
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Apellis Pharmaceuticals Awards Equity Inducement Grant to New Employee - StockTitan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out - AccessWire
Apellis Pharmaceuticals To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO Ahead of Key DME Trial Results - StockTitan
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.89%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):